Clinical trial

A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus…

NCT00197210 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00197210
Title A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
Official title A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Infections, Rotavirus
Intervention type Biological
Interventions Rotavirus
Enrollment 10,708
Start date Dec 1, 2003
Primary completion Jul 1, 2007
Completion Jul 1, 2007
First posted Sep 20, 2005
Last update posted Nov 4, 2016
Countries Singapore

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies